Literature DB >> 8585886

Pharmacokinetics of centchroman in healthy female subjects after oral administration.

J Lal1, O P Asthana, S Nityanand, R C Gupta.   

Abstract

The pharmacokinetics of centchroman, a non-steroidal antifertility agent, were assessed in serum of eleven healthy female subjects after a single 30 mg oral dose. Maximum serum concentration (Cmax) of 55.53 (s.d., 15.45) microgram/L was attained at 5.18 (s.d., 1.78) h after oral administration. The concentration-time profile was best described by a two-compartment open model with bi-exponential disposition functions. The mean terminal elimination half-life (t1/2) was 165 (s.d., 49) h with a clearance of 6.17 (s.d., 1.67) L/h and volume of distribution of 1420 (s.d., 478) L. Comparison of the pharmacokinetic parameters of this study with those obtained after a single 60 mg oral dose did not show statistically significant differences in the rate of absorption, distribution and elimination. The Cmax and AUC0-infinity were dose-dependent. Thus, the absorption and disposition of centchroman are of first-order, reproducible and dose-dependent.

Keywords:  Asia; Biology; Contraception; Contraceptive Methods--pharmacodynamics; Developing Countries; Family Planning; India; Oral Contraceptives--pharmacodynamics; Physiology; Research Report; Southern Asia

Mesh:

Substances:

Year:  1995        PMID: 8585886     DOI: 10.1016/0010-7824(95)00213-t

Source DB:  PubMed          Journal:  Contraception        ISSN: 0010-7824            Impact factor:   3.375


  5 in total

1.  Ormeloxifene Suppresses Prostate Tumor Growth and Metastatic Phenotypes via Inhibition of Oncogenic β-catenin Signaling and EMT Progression.

Authors:  Bilal Bin Hafeez; Aditya Ganju; Mohammed Sikander; Vivek K Kashyap; Zubair Bin Hafeez; Neeraj Chauhan; Shabnam Malik; Andrew E Massey; Manish K Tripathi; Fathi T Halaweish; Nadeem Zafar; Man M Singh; Murali M Yallapu; Subhash C Chauhan; Meena Jaggi
Journal:  Mol Cancer Ther       Date:  2017-06-14       Impact factor: 6.261

Review 2.  Anti-cancer potential of a novel SERM ormeloxifene.

Authors:  Rishi Kumar Gara; Vasudha Sundram; Subhash C Chauhan; Meena Jaggi
Journal:  Curr Med Chem       Date:  2013       Impact factor: 4.530

3.  Ormeloxifene efficiently inhibits ovarian cancer growth.

Authors:  Diane M Maher; Sheema Khan; Jordan L Nordquist; Mara C Ebeling; Nichole A Bauer; Lucas Kopel; Man Mohan Singh; Fathi Halaweish; Maria C Bell; Meena Jaggi; Subhash C Chauhan
Journal:  Cancer Lett       Date:  2014-10-13       Impact factor: 8.679

4.  Scoping review to map evidence on mechanism of action, pharmacokinetics, effectiveness and side effects of centchroman as a contraceptive pill.

Authors:  Rita Kabra; Komal Preet Allagh; Moazzam Ali; Chandani Anoma Jayathilaka; Kasonde Mwinga; James Kiarie
Journal:  BMJ Open       Date:  2019-10-07       Impact factor: 2.692

5.  Comparative differential cytotoxicity of clinically used SERMs in human cancer lines of different origin and its predictive molecular docking studies of key target genes involved in cancer progression and treatment responses.

Authors:  Lakshmi S; Shanitha A; Shiny Dv; Rahul Bs; Saikant R; Shehna Sharaf; Abi Sa; Rajmohan G
Journal:  Curr Res Pharmacol Drug Discov       Date:  2021-12-31
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.